VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2018 | Early RIBECCA results: ribociclib with letrozole for metastatic breast cancer

In this interview, Peter Fasching, MD, from University Hospital Erlangen, Erlangen, Germany, discusses the design and the initial safety results of the Phase III RIBECCA trial (NCT03096847) investigating the efficacy and safety of ribociclib with letrozole for HR+ metastatic or advanced breast cancer. Dr Fasching then compares their results with the previous MONALEESA-2 (NCT01958021) and MONALEESA-3 (NCT02422615) studies, which also focused on the use of ribociclib for breast cancer. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter